Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects

Document Type

Article

Publication Date

10-1-2026

Institution/Department

Internal Medicine; MaineHealth Medical Group Academic Pathway

Journal Title

Journal of Brown hospital medicine

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed as oral hypoglycemic agents for type 2 diabetes (T2D), but mounting evidence has solidified their role as practice-changing therapies for cardiovascular-kidney-metabolic (CKM) syndrome, which includes congestive heart failure (CHF) and chronic kidney disease (CKD). This review summarizes the pivotal randomized controlled trials evaluating SGLT2 inhibitors, highlighting their clinical efficacy, key mechanisms of action, and adverse effects. As indications continue to expand and more patients are prescribed SGLT2 inhibitors, hospitalists must have a thorough understanding of this important medication class.

First Page

171893

Link to Full Text

Share

COinS